Drug Trial Radar · NCT05025332
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Oct 14, 2022
Primary completion
Feb 27, 2024
Study completion May 3, 2024
Sponsor
- Lead sponsor
- Neuren Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.
Conditions
- Pitt Hopkins Syndrome
Interventions
NNZ-2591Drug
NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 13 weeks
- Pharmacokinetic - Mean AUC24Time frame: Pre-dose, 1-3 h post-dose and/or 4-7 h post-dose at Weeks 2, 6 and 13.
- Pharmacokinetic - t1/2Time frame: Pre-dose, 1-3 h post-dose and/or 4-7 h post-dose at Weeks 2, 6 and 13.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California at San Francisco
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rush University Medical Center
Chicago, Illinois
UT Southwestern
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.